Skip to main content
Article thumbnail
Location of Repository

Overexpression of RRM2 decreases thrombspondin-1 and increases VEGF production in human cancer cells in vitro and in vivo: implication of RRM2 in angiogenesis

By Keqiang Zhang, Shuya Hu, Jun Wu, Linling Chen, Jianming Lu, Xiaochen Wang, Xiyong Liu, Bingsen Zhou and Yun Yen
Topics: Research
Publisher: BioMed Central
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (2003). AH: Adenovirus-mediated ribonucleotide reductase R1 gene therapy of human colon adenocarcinoma. Clin Cancer Res
  2. (1995). Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med
  3. (2003). Angiogenesis in health and disease. Nat Med
  4. (2003). Angiogenesis in ischemic and neoplastic disorders. Annu Rev Med
  5. (2003). Angiogenesis: Tumorigenesis and the angiogenic switch. Nature Reviews Cancer
  6. (2005). Association between intratumoral free and total VEGF, soluble VEGFR-1, VEGFR-2 and prognosis in breast cancer.
  7. (2002). BL: What do oncogenic mutations have to do with angiogenesis/vascular dependence of tumors? Cancer Res
  8. (2003). Castellino FJ: Thrombospondin 1-a regulator of adenoma growth and carcinoma progression in the APCMin/+ mouse model. Carcinogenesis
  9. (2001). Characterization of the human ribonucleotide reductase M2 subunit gene; genomic structure and promoter analyses. Cytogenet Cell Genet
  10. (2003). Cohn SL: Methylation-associated silencing of the thrombospondin1 gene in human neuroblastoma. Cancer Res
  11. (2004). EO: Counteraction of pRb-dependent protection after extreme hypoxia by elevated ribonucleotide reductase. Cell Prolif
  12. (2003). G: RRM1-induced metastasis suppression through PTEN-regulated pathways. Oncogene
  13. (1992). Hogenkamp HP: Ribonucleotide diphosphate reductase from human metastatic melanoma. Melanoma Res
  14. (2002). Hypoxia – a key regulatory factor in tumor growth. Nat Rev Cancer
  15. (2001). Iruela-Arispe ML: Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc Natl Acad Sci USA
  16. (1998). JA: The mammalian ribonucleotide reductase R2 component cooperates with a variety of oncogenes in mechanisms of cellular transformation. Cancer Res
  17. (1994). JT: Identification of genes expressed in premalignant breast disease by microscopy-directed cloning.
  18. (2006). Khosravi-Far R: Regulation of tumor angiogenesis by Thrombospondin-1. Biochim Biophys Acta
  19. (2006). Metastasis-suppressing potential of ribonucleotide reductase small subunit p53R2 in human cancer cells. Clin Cancer Res
  20. (1996). Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell
  21. (2003). Ras modμlates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis. Cancer Cell
  22. (2006). Reichard P: Ribonucleotide reductases. Annu Rev Biochem
  23. (1996). Ribonucleotide reductase R2 component is a novel malignancy determinant that cooperates with activated oncogenes to determine transformation and malignant potential.
  24. (1997). Sequential development of an angiogenic phenotype by human fibroblasts progressing to tumorigenicity. Oncogene
  25. (1997). The R1 component of mammalian ribonucleotide reductase has malignancy-suppressing activity as demonstrated by gene transfer experiments. Proc Natl Acad Sci USA
  26. (2001). Thelander L: Mammalian p53R2 protein forms an active ribonucleotide reductase in vitro with the R1 protein, which is expressed both in resting cells in response to DNA damage and in proliferating cells.
  27. (1985). Tribukait B: Cell cycle-dependent expression of mammalian ribonucleotide reductase. Differential regulation of the two subunits.
  28. (2000). Weinberg RA: The Hallmarks of Cancer. Cell
  29. (2004). Whang EE: RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine. Oncogene
  30. (2007). Whang EE: RRM2 induces NF-kappaB-dependent MMP-9 activation and enhances cellular invasiveness.
  31. (2003). Wild-Type p53 regulates human ribonucleotide reductase by protein-protein Interaction with p53R2 as well as RRM2 Subunits. Cancer Res
  32. (2000). Y: A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature
  33. (1998). Y: Determination of deoxyribonucleoside triphosphate pool sizes in ribonucleotide reductase cDNA transfected human KB cells. Biochem Pharmacol
  34. (1998). Y: Overexpression of transfected human ribonucleotide reductase M2 subunit in human cancer cells enhances their invasive potential. Clin Exp Metastasis
  35. (2005). Zetter BR: Inhibition of endothelial cell migration by thrombospondin1 type-1 repeats is mediated by β1 integrins.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.